Functional genomics applications and therapeutic implications in sarcopenia.


Journal

Mutation research. Reviews in mutation research
ISSN: 1388-2139
Titre abrégé: Mutat Res Rev Mutat Res
Pays: Netherlands
ID NLM: 101632211

Informations de publication

Date de publication:
Historique:
received: 31 07 2018
revised: 14 03 2019
accepted: 17 04 2019
entrez: 17 8 2019
pubmed: 17 8 2019
medline: 3 3 2020
Statut: ppublish

Résumé

The human genome contains around 20,000-25,000 genes coding for 30,000 proteins. Some proteins and genes represent therapeutic targets for human diseases. RNA and protein expression profiling tools allow the study of the molecular basis of aging and drug discovery validation. Throughout the life, there is an age-related and disease-related muscle decline. Sarcopenia is defined as a loss of muscle mass and a decrease in functional properties such as muscle strength and physical performance. Yet, there is still no consensus on the evaluation methods of sarcopenia prognosis. The main challenge of this complex biological phenomena is its multifactorial etiology. Thus, functional genomics methods attempt to shape the related scientific approaches via an innovative in-depth view on sarcopenia. Gene and drug high throughput screening combined with functional genomics allow the generation and the interpretation of a large amount of data related to sarcopenia and therapeutic progress. This review focuses on the application of selected functional genomics techniques such as RNA interference, RNA silencing, proteomics, transgenic mice, metabolomics, genomics, and epigenomics to better understand sarcopenia mechanisms.

Identifiants

pubmed: 31416575
pii: S1383-5742(18)30064-4
doi: 10.1016/j.mrrev.2019.04.003
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-185

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Aicha Melouane (A)

CREMI, CHU de Québec Research Center, Quebec, Quebec, G1V 4G2, Canada; Department of Molecular Medicine, Faculty of Medicine, Laval University, Quebec, Quebec, G1V 4G2, Canada.

Abdelaziz Ghanemi (A)

CREMI, CHU de Québec Research Center, Quebec, Quebec, G1V 4G2, Canada; Department of Molecular Medicine, Faculty of Medicine, Laval University, Quebec, Quebec, G1V 4G2, Canada.

Mayumi Yoshioka (M)

CREMI, CHU de Québec Research Center, Quebec, Quebec, G1V 4G2, Canada.

Jonny St-Amand (J)

CREMI, CHU de Québec Research Center, Quebec, Quebec, G1V 4G2, Canada; Department of Molecular Medicine, Faculty of Medicine, Laval University, Quebec, Quebec, G1V 4G2, Canada. Electronic address: Jonny.St-Amand@crchul.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH